Biomarker Research is a leading open access journal published by BMC, dedicated to advancing the field of biomarker discovery and clinical application. Since its inception in 2013, this journal has become a crucial resource for researchers and professionals in biochemistry, clinical biochemistry, and molecular medicine, achieving a prestigious Q1 ranking in each category in 2023. With an E-ISSN of 2050-7771, it maintains a strong reputation for disseminating high-quality research and innovative findings that contribute to the understanding of disease mechanisms and the development of novel diagnostics and therapeutics. The journal is accessible to a global audience, ensuring that vital research is freely available to promote collaboration and accelerate scientific progress. Operating out of the United Kingdom, Biomarker Research plays a significant role in addressing some of the most pressing challenges in medical research, making it an essential resource for academics, clinicians, and industry professionals alike.

Proteomics Clinical Applications, published by Wiley-VCH Verlag GmbH, is a pivotal journal in the realm of Clinical Biochemistry, with an impressive track record since its inception in 2007, continuing its impactful contributions to 2024. With an ISSN of 1862-8346 and an E-ISSN of 1862-8354, this prestigious journal currently holds a commendable Q2 ranking in Clinical Biochemistry, situated at the 54th percentile among its peers within Scopus rankings. Dedicated to the advancement of proteomics and its applications in clinical settings, Proteomics Clinical Applications serves as a bastion for innovative research, fostering knowledge exchange among scientists, healthcare professionals, and students alike. Through its focus on novel methodologies and translational research, the journal aims to bridge the gap between laboratory findings and clinical practice, significantly impacting patient care and outcomes. Although not open access, its content is accessible through various academic databases, ensuring that vital research reaches its intended audience.

Mass Spectrometry Letters is a pioneering open-access journal published by the Korean Society for Mass Spectrometry, specializing in the diverse fields of analytical chemistry, biochemistry, and spectroscopy. Established in 2010, this journal aims to disseminate groundbreaking research and advancements in mass spectrometry and its applications across various scientific domains. Though currently categorized in the Q4 quartile in key analytical fields, Mass Spectrometry Letters serves as an essential platform for researchers, professionals, and students to share innovative methodologies, emerging trends, and practical applications of mass spectrometry, thus fostering collaboration and advancing knowledge in the scientific community. With a commitment to open access, articles published since 2010 are readily available, enabling widespread distribution and engagement within the international research community. Located in Daejeon, South Korea, and actively converging research through 2024, the journal holds the potential to grow its impact and relevance within the dynamic landscape of mass spectrometry.

Biomarkers in Medicine is a prominent academic journal dedicated to advancing the field of medical biochemistry and drug discovery. Published by Future Medicine Ltd in the United Kingdom, this journal aims to provide a platform for researchers, clinicians, and biotechnology professionals to share their findings on the critical role of biomarkers in diagnosis, treatment, and prognosis of various diseases. With a focus on high-quality, peer-reviewed research, Biomarkers in Medicine supports the dissemination of innovative approaches and therapeutic developments across its converged publication years from 2008 to 2024. Rated in the Q3 category for biochemistry (medical), clinical biochemistry, and drug discovery, it occupies a significant place in its field, attracting contributions that push the boundaries of knowledge and application. Although it does not offer open access, the journal remains committed to excellence and rigor in the representation of ground-breaking studies, making it an essential resource for scholars and professionals eager to stay at the forefront of biomarker research.

Molecular Systems Biology, published by SpringerNature, is a premier open access journal that has been a cornerstone in advancing the fields of biological science since its inception in 2005. With its ISSN 1744-4292, this journal exemplifies high scholarly standards, boasting an impressive suite of impact factors, including Q1 rankings across various disciplines such as Agricultural and Biological Sciences, Biochemistry, Genetics and Molecular Biology, and more, highlighting its significant contribution to the scientific community. The journal offers robust access options to facilitate innovative research dissemination, reaching a global audience while maintaining a commitment to fostering collaboration and dialogue among researchers, professionals, and students. With a focus on integrating quantitative approaches to biological systems, Molecular Systems Biology plays a vital role in addressing complex biological questions, paving the way for groundbreaking discoveries and advancements in healthcare, environmental sustainability, and functional genomics.

Current Proteomics is a distinguished journal dedicated to the dynamic field of proteomics, offering researchers and professionals a platform to disseminate innovative findings and comprehensive reviews. Published by Bentham Science Publishers Ltd, this journal caters to a global audience and serves as an essential resource for students, academics, and industry experts interested in advances in biochemistry and molecular biology. With an ISSN of 1570-1646 and an E-ISSN of 1875-6247, the journal has established itself in various research categories, achieving a Q4 ranking in both Biochemistry and Molecular Biology as of 2023. While the impact factor and H-index data are not specified, its Scopus ranking reflects a competitive position in its fields, with percentiles in the 12th to 16th range. Although not an open-access journal, Current Proteomics is vital for fostering ongoing dialogue and collaboration in proteomic research, encouraging contributions that explore cutting-edge methodologies and applications. Researchers are invited to share their insights and contribute to this evolving discipline, thus enhancing the collective understanding of proteomics within the scientific community.

MOLECULAR CANCER RESEARCH, published by the American Association for Cancer Research, stands as a pivotal journal in the fields of cancer research, molecular biology, and oncology. With an impressive impact factor and recognized as a Q1 journal in its respective categories for 2023, it serves as an essential resource for researchers, professionals, and students aimed at advancing our understanding of cancer mechanisms and therapies. The journal, identified by the ISSN 1541-7786 and E-ISSN 1557-3125, provides a platform for cutting-edge research and clinical applications, emphasizing innovation and collaboration within the scientific community. With its focus on high-quality, peer-reviewed articles, MOLECULAR CANCER RESEARCH is vital for anyone looking to stay abreast of significant advancements in cancer biology and treatment strategies. For more details and to access the journal's content, please visit the publisher's link.

Biomarker Insights, published by SAGE Publications Ltd, is a leading open-access journal dedicated to advancing the field of biomarker research and its applications in health and disease. With an ISSN of 1177-2719 and an E-ISSN of 1177-2719, this journal has been at the forefront of disseminating high-quality scientific findings since its inception in 2006. Based in New Zealand, it has achieved a notable impact within the academic community, ranking in Q2 for Biochemistry (medical) and Molecular Medicine, and Q1 in Pharmacology as of 2023. This positions Biomarker Insights as a critical resource for researchers, professionals, and students alike, looking to explore innovative methodologies and applications in biomarker discovery and validation. With a commitment to open access, the journal ensures that groundbreaking research is readily available to the global community, fostering collaboration and innovation in the ever-evolving field of biomedical sciences.

Physiology and Pharmacology is a distinguished open access journal that has been disseminating high-quality research in the fields of physiology and pharmacology since its inception in 1997. Published by the Iranian Society of Physiology & Pharmacology, this journal offers a platform for scholars and practitioners to share innovative findings and advancements that contribute to the understanding of biological systems and drug action. With its ISSN 2476-5236 and E-ISSN 2476-5244, it ensures global reach and accessibility. The journal is positioned in the third quartile for Linguistics and Language and fourth quartile in both Pharmacology and Physiology categories according to Scopus rankings, reflecting a commitment to expanding knowledge within these interdisciplinary domains. Set within the academic landscape of Iran, the journal aims to bridge regional research with the international community, providing valuable insights into physiological processes and pharmacological developments. In light of its open access model, the Physiology and Pharmacology journal plays a crucial role in enhancing the visibility of research outcomes and fostering collaboration among researchers, professionals, and students on a global scale.

AMYLOID - JOURNAL OF PROTEIN FOLDING DISORDERS, published by Taylor & Francis Ltd, is a premier academic journal dedicated to the crucial field of protein folding disorders, offering a vital platform for researchers and healthcare professionals. With an impressive impact factor and classified in the Q1 quartile across both Internal Medicine and Miscellaneous Medicine categories, this journal ranks within the top 15% of its field according to Scopus, with a remarkable rank of #18 out of 167. Covering interdisciplinary approaches that intersect molecular biology, neuroscience, and clinical implications of amyloidosis and related disorders, AMYLOID encourages the dissemination of innovative research findings from 1994 to 2024 and beyond. Despite lacking Open Access options, the journal remains a significant resource for advancing the understanding of protein misfolding diseases, influencing clinical practice and therapeutic developments. With its longstanding commitment to high-quality research, AMYLOID continues to be an essential reading for scholars, practitioners, and students who aim to make significant contributions to this evolving field.